https://doi.org/10.4081/reumatismo.2014.756

Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

Vol. 66 No. 3 (2014)
Submitted: 30 May 2014
Accepted: 29 August 2014
Published: 6 November 2014
Ankylosing spondylitis, Anti-TNF, Remission.
Abstract Views: 2483
PDF: 1396
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

F.M. Perrotta
f.perrotta85@gmail.com
UOC di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Università La Sapienza, Roma, Italy.
O. Addimanda
Unità di Reumatologia, Ospedale di Reggio Emilia, Reggio Emilia, Italy.
R. Ramonda
U.O.C. di Reumatologia, Dipartimento di Medicina DIMED, Università di Padova, Italy.
S. D’Angelo
Dipartimento di Reumatologia della Regione Basilicata, Ospedale San Carlo di Potenza ed Ospedale Madonna delle Grazie, Matera, Italy.
E. Lubrano
Dipartimento di Medicina e Scienze per la Salute, Università del Molise, Campobasso, Italy.
A. Marchesoni
U.O.C. DH Reumatologia, Istituto Ortopedico G. Pini, Milano, Italy.
I. Olivieri
Dipartimento di Reumatologia della Regione Basilicata, Ospedale San Carlo di Potenza ed Ospedale Madonna delle Grazie, Matera, Italy.
L. Punzi
U.O.C. di Reumatologia, Dipartimento di Medicina DIMED, Università di Padova, Italy.
C. Salvarani
Unità di Reumatologia, Ospedale di Reggio Emilia, Reggio Emilia, Italy.
A. Spadaro
UOC di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Università La Sapienza, Roma, Italy.
The objective of this study was to evaluate the predictive factors for achieving partial remission (PR) in patients with ankylosing spondylitis (AS) treated with anti-TNFα. We longitudinally enrolled in a multi-center study 214 AS patients, classified according to New York criteria, treated with anti-TNFα drugs adalimumab (ADA), etanercept (ETA) and infliximab (INF) with at least 12 months of follow up. PR was reached when the score was <20 mm (on a visual analogue scale of 0-100 mm) in each of the following 4 domains: 1) patient global assessment (in the last week); 2) pain (spinal pain); 3) function [measured by the bath ankylosing spondylitis functional index (BASFI)]; 4) inflammation [mean of intensity and duration of morning stiffness, from the bath ankylosing spondylitis disease activity index (BASDAI)]. Two hundred fourteen AS patients (M/F=160/54; median age/range=43.2/19-78 years; median disease duration/ range=96/36-189 months) were treated with ADA (15.8%), ETA (28.9%) and INF (55.1%). At 12 and 24 months, high serum level of C reactive protein (CRP) (≥2 vs ≤0.8 mg/dL) were associated with higher rate of PR in AS patients treated with anti-TNFα drugs. At 24 months, PR was associated with shorter disease duration (≤36 vs ≥189 months) and higher erythrosedimentation rate (ESR) values (≥45 vs ≤17 mm/h). In male patients lower bath ankylosing spondylitis metrology index (BASMI) (≤2 vs ≥6) and absence of psoriasis were associated with higher PR rate only at 12 months. Other parameters assessed before treatment, such as BASDAI, BASFI, peripheral arthritis, inflammatory bowel disease and uveitis were not associated with PR. Our long-term longitudinal study in a setting of clinical practice showed that inflammatory parameters (i.e. CRP, ESR) and disease duration represent the most important predictive variables to achieve PR with an anti-TNFα treatment.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
F.M. Perrotta, UOC di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Università La Sapienza, Roma
specializzando

How to Cite

Perrotta, F., Addimanda, O., Ramonda, R., D’Angelo, S., Lubrano, E., Marchesoni, A., … Spadaro, A. (2014). Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs. Reumatismo, 66(3), 208–214. https://doi.org/10.4081/reumatismo.2014.756

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.